Target intelligence / Profile preview

5S ribosomal RNA pseudogene 454 (RNA5SP454)

Target
RNA5SP454
Molecular classification
Pseudogene, rRNA pseudogene, Non-coding RNA (predicted pseudogene family)
01

Overview

5S ribosomal pseudogene 454 is a member of the rRNA pseudogene family, representing a defective genomic copy of the 5S ribosomal RNA gene. Pseudogenes such as this are characterized by sequence similarity to functional genes but carry disabling mutations that prevent regular transcription or function as rRNA[2][4]. Pseudogenes may be classified as processed (arising from retrotransposition of RNA) or unprocessed, but they typically do not have biological functions associated with the parent gene. The functional 5S ribosomal RNA, by contrast, is an essential structural and regulatory component of the large ribosomal subunit and is required for ribosome assembly and function in protein synthesis[1][3][5]. However, the pseudogene variants are non-functional and are not components of the mature ribosome, nor are they targets for drugs or therapeutics. There are no known drugs, mechanisms of action, biomarker roles, or safety considerations directly connected to pseudogenes like RNA5SP454 in a therapeutic context. Summary of Key Points: - 5S ribosomal pseudogene 454 does not encode functional RNA or protein and is not considered a therapeutic target. - It is principally relevant as a genomic locus for genomic annotation and comparative genomics. - Any biological or disease implication is only hypothetical or indirect via potential regulatory RNA effects; there is no direct evidence of clinical or therapeutic significance for this specific pseudogene.

Other names
RN5S454RNA5SP454RNA, 5S ribosomal 4545S rRNA pseudogene 454
02

Mechanism of action

Not applicable (pseudogenes are not targeted by drugs, and do not encode active products).

03

Biological functions

Pseudogenes, including rRNA pseudogenes, generally lack classical biological function due to disabling mutations.Parent 5S rRNA is involved in ribosome structure and function, but pseudogenes are not functionally active in this role.
04

Disease associations

Some pseudogenes have been implicated in disease, particularly in modulating gene expression networks (including in cancer), but there is no evidence linking this specific pseudogene with disease roles.
05

Safety considerations

None (as it is not a therapeutic target).
06

Interacting drugs

None (pseudogenes are not targeted by classical drugs or therapeutics).
07

Biomarkers

No established biomarker role; some pseudogenes have been explored as RNA expression markers in cancer research generally, but this is not established for RNA5SP454.

Beyond the preview

Go deeper on 5S ribosomal RNA pseudogene 454 (RNA5SP454).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5S ribosomal RNA pseudogene 454 (RNA5SP454).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call